secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086271
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q2 revenue $36.8M, net loss narrows to $1.0M; GAVRETO launch adds $1.9M
-----------------------------------------------------------------------------

- Total Q2 revenue $36.8M; TAVALISSE $26.4M (+24% YoY), REZLIDHIA $5.2M (+102% YoY), GAVRETO $1.9M (launched June 27).
- Net loss narrowed to $1.0M ($0.06/share) from $6.6M loss in Q2 2023; approaching net income break-even.
- Completed NDA transfer of GAVRETO; product commercially available from Rigel beginning June 27.
- Phase 1b trial of R289 in LR-MDS enrolling fourth dose level; preliminary data expected by end of 2024.
- Cash and investments $49.1M as of June 30, essentially flat from March 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924086271/0001104659-24-086271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924086271/tm2420634d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer